Article
Oncology
Cristina Travelli, Giorgia Colombo, Martina Aliotta, Francesca Fagiani, Natalia Fava, Rita De Sanctis, Ambra A. Grolla, Joe G. N. Garcia, Nausicaa Clemente, Paola Portararo, Massimo Costanza, Fabrizio Condorelli, Mario Paolo Colombo, Sabina Sangaletti, Armando A. Genazzani
Summary: Neutralization of eNAMPT with a specific antibody leads to decreased tumor size and reduced number of lung metastases. The study reveals that eNAMPT controls T-cell response through the PD-L1/PD-1 axis, and neutralization of eNAMPT restores antitumoral immune responses by activating CD8+IFN gamma+GrzB+ T cells and reducing the immunosuppressive phenotype of T regulatory cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Priya Rangan, Anna Mondino
Summary: The gut microbiota and its metabolites play a crucial role in regulating metabolic, endocrine, and immune functions. The latest research indicates that short-chain fatty acids (SCFAs) produced by the gut microbiota can influence immune functions by regulating gene expression, cell differentiation, and other aspects, particularly affecting T cell phenotypes and functions.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Charlotte Lemech, Keith Dredge, Darryn Bampton, Edward Hammond, Andrew Clouston, Nigel J. Waterhouse, Amanda C. Stanley, Lucie Leveque-El Mouttie, Grace M. Chojnowski, Andrew Haydon, Nick Pavlakis, Matthew Burge, Michael P. Brown, David Goldstein
Summary: This study evaluated the safety, efficacy, and pharmacodynamics of pixatimod and nivolumab in immunologically cold cancers. The combination therapy showed some antitumor activity in the MSS mCRC cohort, indicating the need for further investigation.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Apple Hui Min Tay, Ruben Prieto-Diaz, Shiyong Neo, Le Tong, Xinsong Chen, Valentina Carannante, Bjorn Onfelt, Johan Hartman, Felix Haglund, Maria Majellaro, Jhonny Azuaje, Xerardo Garcia-Mera, Jose M. Brea, Maria Loza, Willem Jespers, Hugo Gutierrez-de-Teran, Eddy Sotelo, Andreas Lundqvist
Summary: This study synthesized five potent A(2B)AR antagonists and a dual A(2A)AR/A(2B)AR antagonist, and evaluated their therapeutic potential in cancer immunotherapy. The results showed that A(2B)AR antagonists can enhance T and NK cell proliferation, increase cytokine production, and boost lymphocyte infiltration into tumor spheroids without altering adhesion molecule expression.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Shujuan Zhou, Fanyan Meng, Shiyao Du, Hanqing Qian, Naiqing Ding, Huizi Sha, Mei Zhu, Xiaoxiao Yu, Lifeng Wang, Baorui Liu, Jia Wei
Summary: The study introduced a novel bifunctional agent, iRGD-anti-CD3, to enhance T cell infiltration, activation, and cytotoxicity against target cancer cells. The modification significantly inhibited tumor growth and prolonged survival in xenograft mouse models, with additional improvement seen when combined with PD-1 blockade. Mechanistic studies revealed the potential of iRGD-anti-CD3 in promoting T cell extravasation through a transport pathway called vesiculovacuolar organelles in the endothelial cytoplasm.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Meenal Sinha, Courtney Betts, Li Zhang, Madeline J. Griffith, Isabelle Solman, Brandon Chen, Eric Liu, Whitney Tamaki, Jacob Stultz, Jaqueline Marquez, Shamilene Sivagnanam, Alexander Cheung, Denise Pener, Anne Fahlman, Erin Taber, Kimberly Lerner, Matthew Crocker, Kendra Todd, Brindha Rajagopalan, Clarisha Ware, Mark Bridge, Johnson Vo, Hannah Dragomanovich, Julie Sudduth-Klinger, Gina Vaccaro, Charles D. Lopez, Margaret Tempero, Lisa M. Coussens, Lawrence Fong
Summary: In preclinical studies, ibrutinib improved the antitumor efficacy of chemotherapy for PDAC. A phase 1b clinical trial was conducted to determine the safety, tolerability, and immunologic effects of ibrutinib treatment in advanced PDAC patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Florian J. Sulzmaier, Nadja Kern, Sae Jeong Ahn, Anya Polovina, Jason Ho, Abrahim Hussain, Garrett Cyprus, Chelsie Macedo, Rajay Pandit, William Crago, Emily Rowell, John C. Timmer, Brendan P. Eckelman
Summary: INBRX-120 is a CD8 alpha-targeted Cisleukin (TM) molecule that selectively activates and expands the antitumor activity of CD8 T cells and natural killer cells without affecting regulatory T cells. It demonstrates good safety and pharmacodynamic profile.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Briana Rose Halle, Allison Betof Warner, Farzana Y. Zaman, Andrew Haydon, Prachi Bhave, Anna K. Dewan, Fei Ye, Rebecca Irlmeier, Paras Mehta, Nicholas R. Kurtansky, Mario E. Lacouture, Jessica C. Hassel, Jacob S. Choi, Jeffrey A. Sosman, Sunandana Chandra, Tracey S. Otto, Ryan Sullivan, Meghan J. Mooradian, Steven T. Chen, Florentia Dimitriou, Georgina Long, Matteo Carlino, Alexander Menzies, Douglas B. Johnson, Veronica M. Rotemberg
Summary: A retrospective cohort study on patients with pre-existing psoriasis receiving ICIs for cancer treatment showed that most patients experienced psoriasis exacerbation after treatment, but it was manageable with standard therapies; some patients also experienced other immune-related adverse events; patients with disease exacerbation performed well in terms of progression-free survival compared to those who did not.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
James L. Alexander, Hajir Ibraheim, Bhavisha Sheth, Jessica Little, Muhammad Saheb Khan, Camellia Richards, Nikki Hunter, Dharmisha Chauhan, Raguprakash Ratnakumaran, Kathleen McHugh, David J. Pinato, Paul Nathan, Julia Choy, Shanthini M. Crusz, Andrew Furness, Samra Turajlic, Lisa Pickering, James Larkin, Julian P. Teare, Sophie Papa, Ally Speight, Anand Sharma, Nick Powell
Summary: This study investigated the outcomes of patients with corticosteroid-refractory CPI-induced enterocolitis treated with IFX, finding that less than half of patients achieved corticosteroid-free clinical remission. The data also suggest that cancer outcomes may be better in patients developing prolonged and severe inflammatory side effects of CPI therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
David B. Rosen, Anne Mansson Kvarnhammar, Burkhardt Laufer, Thomas Knappe, Jens Jakob Karlsson, Enping Hong, Yu-Chi Lee, Dhruv Thakar, Luis Alejandro Zuniga, Kathy Bang, Simran Singh Sabharwal, Karan Uppal, Janne Damm Olling, Kristian Kjaergaard, Thomas Kurpiers, Meike Schnabel, Diana Reich, Philipp Glock, Joachim Zettler, Mathias Krusch, Ana Bernhard, Stefan Heinig, Valentino Konjik, Thomas Wegge, Yvonne Hehn, Steffen Killian, Laura Viet, Josefine Runz, Frank Faltinger, Mohammad Tabrizi, Kristin Laura Abel, Vibeke Miller Breinholt, Stina M. Singel, Kennett Sprogoe, Juha Punnonen
Summary: Recombinant interleukin-2 (IL-2) is an approved cancer immunotherapy, but it has severe toxicities and suboptimal pharmacokinetics. TransCon IL-2 beta/gamma is a novel prodrug designed to address these issues, showing sustained release of IL-2 and potential antitumor activity in animal models.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Maria Hinterberger, Raphael Giessel, Giovanna Fiore, Fabienne Graebnitz, Barbara Bathke, Sonia Wennier, Paul Chaplin, Ignacio Melero, Mark Suter, Henning Lauterbach, Pedro Berraondo, Hubertus Hochrein, Jose Medina-Echeverz
Summary: Intratumoral virotherapy with MVA-TAA-4-1BBL led to control of established tumors, triggering proinflammatory changes and immunogenic cell death in the tumor microenvironment. This approach induced reactivation and expansion of potent tumor-specific CD8(+) T cells, resulting in tumor elimination and protective immunological memory against tumor rechallenge.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Pankti Reid, David F. L. Liew, Rajshi Akruwala, Anne R. Bass, Karmela K. Chan
Summary: The study identified a new adverse event of ICI immunotherapy called post-ICI-activated osteoarthritis (ICI-aOA). Patients with ICI-aOA experienced increased joint pain after ICI treatment, affecting joints commonly seen in osteoarthritis such as large joints (hip/knee) and small joints in the hands.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Rebecca Ibrahim, Khalil Saleh, Claude Chahine, Rita Khoury, Nadine Khalife, Axel Le Cesne
Summary: The discovery of immunotherapy is an important step forward in cancer management, but its benefits are limited and new treatment methods are needed. LAG-3, as an immune checkpoint, plays a crucial role in regulating the immune system and is considered a potential target for cancer treatment.
Review
Biochemistry & Molecular Biology
Chi Ma, Verena Martinez-Rodriguez, Peter R. Hoffmann
Summary: The selenoprotein family comprises 25 members, with SELENOI being a unique member functioning as an ethanolamine phosphotransferase. SELENOI plays a crucial role in the synthesis of cellular membrane constituents, impacting metabolic reprogramming and proliferative capacity in T cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Vladimir Laletin, Pierre-Louis Bernard, Cathy Costa da Silva, Geoffrey Guittard, Jacques A. Nunes
Summary: Immunotherapy strategies targeting T cells have been effective in treating cancer by blocking immune checkpoints. However, many patients do not respond to these treatments, so alternative approaches are needed. In addition to membrane-associated inhibitory molecules, intracellular immune checkpoints (iICPs) may also downregulate TCR signaling and inhibiting them shows promise for future cancer immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Letter
Hematology
Omar Mamlouk, Ranjit Nair, Swaminathan P. Iyer, Angelina Edwards, Sattva S. Neelapu, Raphael E. Steiner, Sherry A. Adkins, Misha Hawkins, Neeraj Saini, Kartik Devashish, Paolo Strati, Sreedhar Mandayam, Sairah Ahmed
Article
Urology & Nephrology
Christopher D. Hamad, Zachary C. Hoelscher, Amanda Tchakarov, Jaya Kala
Summary: In cancer patients, thrombotic microangiopathy (TMA) is a common complication that can be caused by either the cancer itself or anticancer therapy. The incidence of TMA from anticancer therapy has been found to be over 15% since the introduction of anti-angiogenic drugs. However, it is important to consider other potential causes of TMA, such as bacterial or viral infections, antiplatelet drugs, genetic complement mutations, and autoimmune disorders. This case highlights the importance of identifying the true cause of TMA to prevent unnecessary discontinuation of life-saving anticancer drugs after TMA resolution.
Article
Immunology
Praveen Ratanasrimetha, Vikas D. Reddy, Jaya Kala, Amanda Tchakarov, William F. Glass, Pavlos Msaouel, Jamie S. Lin
Summary: This report describes the first suspected case of late-onset immune checkpoint inhibitor (ICI)-associated membranous nephropathy (MN). It emphasizes the complexity of recognizing renal immune-related adverse events (irAEs) in the context of increasing use of ICIs in combination with other cancer therapies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Shailbala Singh, Leticia C. Clemente, Edwin R. Parra, Amanda Tchakarov, Chao Yang, Yisheng Li, James P. Long, Cassian Yee, Jamie S. Lin
Summary: Acute kidney injury (AKI) occurs in approximately 20% of patients receiving immune checkpoint inhibitor (ICI) therapy, but only a small percentage of them develop ICI-mediated immune nephritis. Traditional diagnostic tests are not specific enough for disease pathology, and invasive procedures may not be feasible. This study demonstrates the presence of urinary T cells in patients with immune nephritis and the enrichment of kidney T cell receptor (TCR) sequences in urine. Noninvasive assessment of urinary immune cells in ICI therapy recipients can enhance clinical management and personalize ICI-nephritis treatment.
Article
Oncology
Ala Abudayyeh, Liye Suo, Heather Lin, Omar Mamlouk, Noha Abdel-Wahab, Amanda Tchakarov
Summary: This study evaluated clinical variables and pathological findings to identify predictors of renal response and overall survival in patients with immune checkpoint inhibitor-induced acute interstitial nephritis (AIN). The findings suggest that low levels of interstitial fibrosis in kidney tissue are associated with renal response to treatment, and concurrent use of immune checkpoint inhibitors is associated with better overall survival in these patients.
Letter
Hematology
Omar Mamlouk, Paolo Strati, Lei Feng, Ryan Sun, Amy Ayers, Raphael E. Steiner, Ranjit Nair, Christopher Flowers, Jeremy L. Ramdial, Neeraj Saini, Samer A. Srour, Richard E. Champlin, Partow Kebriaei, Loretta J. Nastoupil, Maria A. Rodriguez, Elizabeth J. Shpall, Yago Nieto, Jason Westin, Sattva S. Neelapu, Sreedhar Mandayam, Sairah Ahmed
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Urology & Nephrology
Prakash Gudsoorkar, Ala Abudayyeh, Amanda Tchakarov, Ramy Hanna
Summary: Thrombotic microangiopathies (TMAs) encompass a complex interplay of endothelial and podocyte biology, nephron physiology, complement genetics, and cancer therapy with host immunology. The complexities of molecular causes, genetic expressions, immune system mimicking, and incomplete penetrance make it challenging to find a straightforward solution. Therefore, consensus in diagnosis, research, and treatment approaches can be difficult to achieve.
SEMINARS IN NEPHROLOGY
(2022)
Article
Gastroenterology & Hepatology
Rohit Josyabhatla, Cristoniel Abrenica, Tu Mai, Syed Shahrukh Hashmi, Yuying Liu, Ricardo Mosquera, Melissa Van Arsdall, Fernando Navarro, Amanda Tchakarov, Nina Tatevian, Guoyao Wu, Jon Marc Rhoads
Summary: This study aimed to identify non-invasive markers to help identify patients with active EoE. The results showed that a combination score, including fractionated exhaled nitric oxide, peripheral absolute eosinophil count, plasma amino acids, and plasma polyamine analysis, can be used as a non-invasive tool to differentiate active EoE patients from controls.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2023)
Article
Medical Laboratory Technology
Anindita Ghosh, Amanda Tchakarov, Norma Perez, Nina Tatevian, Meenakshi Bhattacharjee
Summary: This article presents a rare case of co-infection with tuberculosis and SARS-CoV-2 in a 6-month-old infant. The patient developed severe complications, including strokes and multi-organ failure. Laboratory and autopsy findings shed light on the immunological and pathological aspects of co-occurring infectious diseases.
ANNALS OF CLINICAL AND LABORATORY SCIENCE
(2022)
Article
Medical Laboratory Technology
Brenda Mai, Mesk Alrais, Amanda Tchakarov
Summary: COVID-19 has unknown effects on pregnant women with adverse perinatal outcomes reported, including pre-eclampsia, miscarriage, pre-term labor, and stillbirth. Histopathological examination of COVID-19 placentas provides significant data for maternal and fetal health. A case study of a COVID-19-positive pregnant woman with fetal thrombotic vasculopathy (FTV) in the placenta highlights the importance of prenatal care management during the pandemic.
ANNALS OF CLINICAL AND LABORATORY SCIENCE
(2021)
Article
Urology & Nephrology
Anna Strasma, Howard Coke, Omar Mamlouk, Amanda Tchakarov, Sreedhar Mandayam
Summary: Drug-induced lupus glomerulonephritis can be caused by new drugs such as multitarget tyrosine kinases like regorafenib. A patient developed acute kidney injury, proteinuria, and hematuria months after starting regorafenib therapy for metastatic colon cancer. The kidney injury improved with corticosteroid treatment and discontinuation of regorafenib therapy.
Article
Oncology
Jamie S. Lin, Omar Mamlouk, Umut Selamet, Amanda Tchakarov, William F. Glass, Rahul A. Sheth, Rachel M. Layman, Ramona Dadu, Noha Abdelwahab, Maen Abdelrahim, Adi Diab, Cassian Yee, Ala Abudayyeh
Summary: Infliximab may be a treatment option for achieving durable and complete renal recovery in patients with CPI-ATIN, representing a potential steroid-sparing strategy in challenging cases. Rigorous clinical studies are needed to evaluate the risk-benefit analysis for infliximab usage in CPI-ATIN patients.